| EGFR inhibitor |
| Gefitinib (JP18/USAN/INN) <JP/US> |
| Erlotinib |
| Erlotinib (INN) |
| Erlotinib hydrochloride (JAN/USAN) <JP/US> |
| Afatinib |
| Afatinib (USAN/INN) |
| Afatinib dimaleate (USAN); Afatinib maleate (JAN) <JP/US> |
| Osimertinib mesylate (USAN); Osimertinib mesilate (JAN) <JP/US> |
| Rociletinib (USAN/INN) |
| Olmutinib |
| Olmutinib (USAN/INN) |
| Olmutinib hydrochloride (USAN) |
| Dacomitinib |
| Dacomitinib (INN) |
| Dacomitinib (USAN); Dacomitinib hydrate (JAN) <JP/US> |
| Icotinib |
| Lazertinib |
| Lazertinib (USAN) |
| Lazertinib mesilate hydrate (JAN) |
| Aumolertinib |
| Aumolertinib (USAN/INN) |
| Aumolertinib mesylate (USAN) |
| Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN) <JP/US> |
| Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN) <JP/US> |
| Necitumumab (USAN/INN); Necitumumab (genetical recombination) (JAN) <JP/US> |
| Amivantamab (USAN/INN); Amivantamab (genetical recombination) (JAN) <US> |
| Tuxobertinib (USAN/INN) |
| Sunvozertinib (USAN/INN) |
| Tigozertinib (USAN) |
| Pebezertinib (USAN) |
| HER2 inhibitor |
| Lapatinib |
| Lapatinib (INN) |
| Lapatinib ditosylate (USAN); Lapatinib tosilate hydrate (JAN) <JP/US> |
| Neratinib |
| Neratinib (USAN/INN) |
| Neratinib maleate <US> |
| Tucatinib |
| Tucatinib (USAN/INN) <US> |
| Tucatinib ethanolate (JAN) |
| Trastuzumab (USAN/INN); Trastuzumab (genetical recombination) (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN) <JP/US> |
| Trastuzumab and hyaluronidase <US> |
| Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN) <JP/US> |
| Trastuzumab emtansine (USAN/INN); Trastuzumab emtansine (genetical recombination) (JAN) <JP/US> |
| Trastuzumab deruxtecan (USAN/INN); Trastuzumab deruxtecan (genetical recombination) (JAN) <JP/US> |
| Trastuzumab duocarmazine (USAN/INN) |
| Margetuximab (USAN/INN) <US> |
| VEGFR inhibitor |
| Axitinib (JAN/USAN) <JP/US> |
| Cediranib |
| Cediranib (USAN/INN) |
| Cediranib maleate (JAN/USAN) |
| Tivozanib |
| Tivozanib (USAN/INN) |
| Tivozanib hydrochloride (USAN) <US> |
| FGFR inhibitor |
| Erdafitinib (JAN/USAN/INN) <US> |
| Pemigatinib (JAN/USAN/INN) <JP/US> |
| Infigratinib |
| Infigratinib (USAN/INN) |
| Infigratinib phosphate (USAN) |
| Futibatinib (JAN/USAN/INN) <JP/US> |
| Mobocertinib |
| Mobocertinib (USAN/INN) |
| Mobocertinib succinate (JAN) <US> |
| Fruquintinib (JAN/USAN) <US> |
| Sunitinib |
| Sunitinib (INN) |
| Sunitinib malate (JAN/USAN) <JP/US> |
| Pazopanib hydrochloride (JAN/USAN) <JP/US> |
| Vandetanib (JAN/USAN/INN) <JP/US> |
| Regorafenib |
| Regorafenib (USAN/INN) |
| Regorafenib hydrate (JAN) <JP/US> |
| Masitinib (INN) |
| Cabozantinib |
| Cabozantinib (USAN) |
| Cabozantinib s-malate (USAN); Cabozantinib malate (JAN) <JP/US> |
| Lenvatinib |
| Lenvatinib (USAN/INN) |
| Lenvatinib mesylate (USAN); Lenvatinib mesilate (JAN) <JP/US> |
| Midostaurin (JAN/USAN/INN) <US> |
| Quizartinib |
| Quizartinib (USAN/INN) |
| Quizartinib dihydrochloride (USAN); Quizartinib hydrochloride (JAN) <JP/US> |
| Gilteritinib |
| Gilteritinib (USAN/INN) |
| Gilteritinib fumarate (JAN/USAN) <JP/US> |
| Capmatinib |
| Capmatinib (USAN/INN) |
| Capmatinib hydrochloride (USAN); Capmatinib hydrochloride hydrate (JAN) <JP/US> |
| Avapritinib (USAN/INN) <US> |
| Ripretinib (USAN) <US> |
| Tepotinib |
| Tepotinib (USAN/INN) |
| Tepotinib hydrochloride (USAN); Tepotinib hydrochloride hydrate (JAN) <JP/US> |
| Sitravatinib |
| Sitravatinib (USAN/INN) |
| Sitravatinib malate (USAN) |
| Motesanib |
| Motesanib (USAN) |
| Motesanib diphosphate (USAN); Motesanib phosphate (JAN) |
| Varlitinib |
| Varlitinib (USAN/INN) |
| Varlitinib tosylate (USAN) |
| Crenolanib |
| Crenolanib (USAN) |
| Crenolanib besylate (USAN) |
| Toceranib |
| Toceranib (USAN) |
| Toceranib phosphate (USAN) |
| Golvatinib |
| Golvatinib (USAN) |
| Golvatinib tartrate (USAN) |
| Brivanib |
| Brivanib (USAN) |
| Brivanib alaninate (JAN/USAN/INN) |
| Rivoceranib |
| Rivoceranib (USAN/INN) |
| Rivoceranib mesylate (USAN) |
| Nazartinib |
| Nazartinib (USAN/INN) |
| Nazartinib mesylate (USAN) |
| Dubermatinib |
| Dubermatinib (USAN/INN) |
| Dubermatinib tartrate (USAN) |
| Tesevatinib |
| Tesevatinib (USAN/INN) |
| Tesevatinib tosylate (USAN) |
| Naquotinib |
| Naquotinib (USAN/INN) |
| Naquotinib mesylate (USAN); Naquotinib mesilate (JAN) |
| Tasurgratinib |
| Tasurgratinib (INN) |
| Tasurgratinib succinate (JAN) |
| Zanzalintinib |
| Zanzalintinib (USAN/INN) |
| Zanzalintinib fumarate (USAN) |
| Canertinib dihydrochloride (USAN) |
| Mubritinib (USAN/INN) |
| Lestaurtinib (USAN/INN) |
| Pelitinib (USAN/INN) |
| Semaxanib (USAN/INN) |
| Tandutinib (USAN/INN) |
| Vatalanib (USAN/INN) |
| Dovitinib lactate (USAN); Dovitinib lactate hydrate (JAN) |
| Foretinib (USAN/INN) |
| Linifanib (USAN/INN) |
| Pegdinetanib (USAN/INN) |
| Tivantinib (JAN/USAN/INN) |
| Altiratinib (USAN) |
| Glesatinib (USAN/INN) |
| Savolitinib (USAN/INN) |
| Mavelertinib (USAN/INN) |
| Bemcentinib (USAN/INN) |
| Derazantinib hydrochloride (USAN) |
| Fisogatinib (USAN/INN) |
| Briquilimab (USAN/INN) |
| Elzovantinib (USAN/INN) |
| Bezuclastinib (USAN/INN) |
| Gumarontinib hydrate (JAN) |
